Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AVDL vs ALVO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Captures Overall Composite Edge (62.9 BUY vs 52.2 HOLD), While ALVO Leads 4–1 on Growth & Valuation Pillars

AVDL Overall Winner 6-Pillar Tally: AVDL 1 – 4 ALVO (1 Tie) Matrix Metrics: AVDL 6 – 4 ALVO

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Alvotech (ALVO) on higher Unified Composite conviction (62.9/100 BUY vs. 52.2/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale), while ALVO wins 4–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus ALVO at $4.12 (19.4x Forward P/E, 12.9% operating margin).

  • Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. ALVO 52.2/100 HOLD) and 0.14β · 2% Vol risk profile, whereas ALVO leads top-line expansion (-2.0% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile ALVO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVDL vs ALVO
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
ALVO NASDAQ
Alvotech Ordinary Shares
Biological Products, (No Diagnostic Substances)
$4.12
-3.96% 1D
Market Cap $1.5B
TTM Revenue $492M
Forward P/E 19.4x
Beta / 30D Vol 0.73β · 68% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.9%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $4.60 · SMA50: $5.14

6-Pillar Scorecard Institutional Category Breakdown (AVDL 1 – 4 ALVO)

Columns: Metric · AVDL · ALVO
1. Valuation Multiples ALVO
Forward P/E 28.8x 19.4x
Trailing P/E 16.8x 15.2x
PEG Ratio 0.07x N/M
EV / Revenue 8.5x 3.1x
2. Growth & Scale AVDL
Revenue Growth (YoY) +54.9% -2.0%
Earnings Growth (YoY) +0.0% -99.0%
TTM Revenue (USD) $249M $492M
Market Cap $2.1B $1.5B
3. Profitability & Quality ALVO
Gross Margin 94.9% 57.1%
Operating Margin 2.5% 12.9%
Net Profit Margin -0.1% -50.6%
Return on Equity (ROE) -0.3% 0.0%
4. Balance Sheet & Cash Flow ALVO
Cash Generation (TTM) $2.7M EBITDA $89M EBITDA
Cash Flow Margin 1.1% EBITDA Mgn 18.1% EBITDA Mgn
Net Cash / Leverage $1.01 Book/Sh · -0.3% ROE 0.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 2.4% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ALVO
OpEx & R&D Intensity N/A 44.2% of Rev ($218M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVDL (6) vs ALVO (4)
Institutional Metric AVDL ALVO Criterion Row Edge
Market Capitalization
Scale
$2.1B $1.5B Larger Scale AVDL
Trailing P/E Ratio
Valuation
16.8x 15.2x Lower Multiple ALVO
Forward P/E Ratio
Valuation
28.8x 19.4x Lower Multiple ALVO
Revenue Growth (YoY)
Growth
+54.9% -2.0% Higher Growth AVDL
Operating Margin (TTM)
Profitability
2.5% 12.9% Higher Margin ALVO
Net Profit Margin
Profitability
-0.1% -50.6% Higher Margin AVDL
Return on Equity (ROE)
Capital Efficiency
-0.3% 0.0% Higher ROE ALVO
52-Week Range Position
Momentum
89% ($6–$24) 33% ($3–$7) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol 0.73β · 68% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 52.2 / 100 (HOLD) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M $492M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9% 57.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) $89M EBITDA (0.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVDL +2.27 pp
AVDL: +0.65% · ALVO: -1.62%
3M Horizon AVDL +0.95 pp
AVDL: -6.32% · ALVO: -7.27%
6M Horizon AVDL +0.95 pp
AVDL: -6.32% · ALVO: -7.27%
1Y Horizon AVDL +0.95 pp
AVDL: -6.32% · ALVO: -7.27%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs ALVO. Trailing 12-month operating profitability (AVDL 2.5% vs ALVO 12.9%) and valuation multiples (AVDL 28.8x vs ALVO 19.4x Forward P/E) are benchmarked directly in Pillar 4 below.

AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x
ALVO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$492M
Gross Margin57.1%
Op. Margin12.9%
ROE / Fwd P/E0.0% · 19.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ALVO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ALVO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ALVO Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.5B market capitalization and 12.9% operating margin.
OpEx & R&D Reinvestment 44.2% of Rev ($218M)
90D Engineering Disclosures 0 Published

Investor FAQ AVDL vs ALVO Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Alvotech (ALVO) on higher Unified Composite conviction (62.9/100 BUY vs. 52.2/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale), while ALVO wins 4–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus ALVO at $4.12 (19.4x Forward P/E, 12.9% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. ALVO 52.2/100 HOLD) and 0.14β · 2% Vol risk profile, whereas ALVO leads top-line expansion (-2.0% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile ALVO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with ALVO at -2.0% YoY revenue growth and -99.0% YoY earnings growth on $492M TTM revenue (57.1% gross margin, 12.9% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $492M for ALVO. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 44.2% of Rev ($218M) (0 disclosures) for ALVO.

ALVO screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas ALVO trades at 19.4x Forward P/E, 15.2x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (18.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus ALVO (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, ALVO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.73β · 68% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.